Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals

globenewswire.com
NVS Novartis' LEQVIO, an siRNA-based therapeutic, is highlighted for its effectiveness in reducing LDL-C levels, showcasing a unique approach to cholesterol control. ALNY Alnylam Pharmaceuticals is recognized as a pioneer in RNA interference, with AMVUTTRA targeting transthyretin-mediated amyloidosis and expanding treatment options for rare diseases. They are also identified as an industry leader driving innovation. IONS Ionis Pharmaceuticals is mentioned as an industry leader driving innovation in oligonucleotide therapeutics through novel technologies and strategic partnerships.

Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Oligonucleotides - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.

The report delves into the realm of oligonucleotides, providing extensive insights into over 280 companies and 320 drugs. It assesses therapeutics by product type, stage, administration route, and molecule type, also focusing on the inactive pipeline products. This report is a crucial resource for understanding the global landscape of oligonucleotides, a transformative class of drugs with the potential to treat a wide spectrum of genetic and acquired disorders.

Oligonucleotide therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), face significant challenges in terms of delivery due to large molecular weight, hydrophilicity, and susceptibility to degradation, but innovations like GalNAc conjugation are enhancing delivery and specificity.

Recent therapeutic developments include:

The report further profiles key companies and products, offering insights into their development processes and strategic initiatives. Novartis' LEQVIO, for instance, an siRNA-based therapeutic, has proven effective in reducing LDL-C levels. Approved by MHLW, it showcases a unique therapeutic approach in controlling cholesterol.

Astellas Pharma's IZERVAY is another spotlight product, designed for geographic atrophy treatment, demonstrating the efficacy of RNA aptamers in reducing inflammation related to AMD.

Alnylam Pharmaceuticals continues to pioneer RNA interference with AMVUTTRA, targeting transthyretin-mediated amyloidosis and expanding treatment options for rare diseases.

The competitive landscape is further enriched by detailed company analyses covering mergers, strategic collaborations, licensing activities, and pipeline assessments. The report's extensive evaluation includes unmet needs, upcoming therapies, and company comparisons, ensuring stakeholders have the insights needed to navigate this dynamic sector.

Industry leaders such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Astellas Pharma continue to drive innovation, leveraging novel technologies and strategic partnerships to advance oligonucleotide therapeutics.

This report is an essential resource for understanding the evolving landscape of oligonucleotides, aiding professionals in identifying key trends and emerging opportunities in precision medicine. The in-depth commercial assessments and detailed company profiles position it as a cornerstone document for stakeholders engaged in the biotechnology and pharmaceuticals sectors.

Highlights

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/yok27o

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.